Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis
Overview
Authors
Affiliations
Infections by the Epstein-Barr virus (EBV) are often at the disease onset of patients suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). However, serological analyses of these infections remain inconclusive when comparing patients with healthy controls (HCs). In particular, it is unclear if certain EBV-derived antigens eliciting antibody responses have a biomarker potential for disease diagnosis. With this purpose, we re-analyzed a previously published microarray data on the IgG antibody responses against 3,054 EBV-related antigens in 92 patients with ME/CFS and 50 HCs. This re-analysis consisted of constructing different regression models for binary outcomes with the ability to classify patients and HCs. In these models, we tested for a possible interaction of different antibodies with age and gender. When analyzing the whole data set, there were no antibody responses that could distinguish patients from healthy controls. A similar finding was obtained when comparing patients with non-infectious or unknown disease trigger with healthy controls. However, when data analysis was restricted to the comparison between HCs and patients with a putative infection at their disease onset, we could identify stronger antibody responses against two candidate antigens (EBNA4_0529 and EBNA6_0070). Using antibody responses to these two antigens together with age and gender, the final classification model had an estimated sensitivity and specificity of 0.833 and 0.720, respectively. This reliable case-control discrimination suggested the use of the antibody levels related to these candidate viral epitopes as biomarkers for disease diagnosis in this subgroup of patients. To confirm this finding, a follow-up study will be conducted in a separate cohort of patients.
Naiditch H, Betts M, Larman H, Levi M, Rosenberg A Front Immunol. 2025; 15:1376654.
PMID: 40012912 PMC: 11861071. DOI: 10.3389/fimmu.2024.1376654.
Gayer M, Xu Z, Hodel F, Preisig M, Strippoli M, Vollenweider P Brain Behav Immun Health. 2024; 42:100896.
PMID: 39624483 PMC: 11609321. DOI: 10.1016/j.bbih.2024.100896.
Li X, Chen S, Wu Y, Qiu G, Cheng S, Lan H Skin Res Technol. 2024; 30(8):e13875.
PMID: 39120064 PMC: 11311118. DOI: 10.1111/srt.13875.
Pricoco R, Meidel P, Hofberger T, Zietemann H, Mueller Y, Wiehler K Front Pediatr. 2024; 11:1266738.
PMID: 38304441 PMC: 10830704. DOI: 10.3389/fped.2023.1266738.
Fonseca A, Szysz M, Ly H, Cordeiro C, Sepulveda N Medicina (Kaunas). 2024; 60(1).
PMID: 38256421 PMC: 10820613. DOI: 10.3390/medicina60010161.